LIBRITABS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIBRITABS (LIBRITABS).
Libritabs (chlordiazepoxide) is a benzodiazepine that binds to GABA-A receptors at the gamma subunit, potentiating GABAergic inhibition and producing anxiolytic, sedative, and anticonvulsant effects.
| Metabolism | Primarily hepatic via CYP3A4 and CYP2C19; active metabolite desmethylchlordiazepoxide. |
| Excretion | Renal: 70-80% as unchanged drug and glucuronide conjugate; fecal: 15-20% via biliary elimination. |
| Half-life | Terminal elimination half-life is 15-20 hours; clinical context: steady-state reached in 3-5 days with daily dosing, prolonged in hepatic impairment. |
| Protein binding | 85-90% bound, primarily to albumin. |
| Volume of Distribution | 0.8-1.2 L/kg; clinical meaning: extensive tissue distribution, moderate lipophilicity. |
| Bioavailability | Oral: 85-95%; IM: 90-100%; rectal: 80-90%. |
| Onset of Action | Oral: 30-60 minutes; IV: 1-5 minutes; IM: 15-30 minutes. |
| Duration of Action | 5-8 hours for anxiolytic effect; clinical context: single dose effects last 6-8 hours, prolonged with accumulation. |
5-10 mg orally 3-4 times daily; up to 30 mg/day in divided doses for severe anxiety.
| Dosage form | TABLET |
| Renal impairment | GFR 10-50 mL/min: decrease dose by 25-50%; GFR <10 mL/min: avoid use or reduce by 50% and monitor for excessive sedation. |
| Liver impairment | Child-Pugh class A: no adjustment needed; class B: reduce dose by 50%; class C: avoid use or reduce by 75%. |
| Pediatric use | Children 6-12 years: 5 mg orally 2-4 times daily; not recommended under 6 years. |
| Geriatric use | Initiate at 2-2.5 mg orally 1-2 times daily; increase gradually to avoid oversedation and falls; maximum 10 mg/day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LIBRITABS (LIBRITABS).
| Breastfeeding | Chlordiazepoxide is excreted into breast milk; reported M/P ratio approximately 0.5. Risk of infant sedation and poor feeding. Use with caution; monitor infant for drowsiness and weight gain. AAP considers use compatible with breastfeeding but with caution. |
| Teratogenic Risk | Chlordiazepoxide (Libritabs) is a benzodiazepine. First trimester: Increased risk of congenital malformations (e.g., cleft lip/palate) based on some studies. Second/third trimester: Risk of fetal CNS depression, hypotonia, respiratory depression, and withdrawal symptoms (floppy infant syndrome). |
■ FDA Black Box Warning
Concomitant use of benzodiazepines with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
| Serious Effects |
["Hypersensitivity to chlordiazepoxide or any benzodiazepine","Narrow-angle glaucoma","Concurrent use with opioids (except in specific monitored settings)"]
| Precautions | ["Risk of respiratory depression, especially with concurrent CNS depressants","Potential for dependence and withdrawal reactions","May impair cognitive and motor function","Use with caution in patients with hepatic impairment"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal vital signs and level of sedation. Fetal monitoring: assess fetal growth and amniotic fluid volume. Neonatal monitoring after delivery for signs of withdrawal or CNS depression. |
| Fertility Effects | No specific human data on fertility effects. In animal studies, high doses may impair fertility. Menstrual irregularities and amenorrhea reported with chronic use. |